Noah L.  Rosenberg net worth and biography

Noah Rosenberg Biography and Net Worth

quote marks icon
We have the power to heal, the passion to help, and the ability to execute.

quote marks icon
Noah Rosenberg, M.D., has served as chief medical officer of Travere Therapeutics since July 2018 and is responsible for overseeing the company’s clinical development, as well as clinical operations, pharmacokinetics, medical affairs, patient advocacy and pharmacovigilance. He brings more than 20 years of clinical and therapeutic development experience, including advancing several mid- and late-stage programs across therapeutic areas through to commercialization.

Previously, Dr. Rosenberg served as chief medical officer at Medimetriks Pharmaceuticals where he was responsible for the clinical development and medical strategy for pipeline candidates and multiple product launches. He also served as chief medical officer of Esperion Therapeutics, where he led the design, protocol implementation, execution and monitoring of innovative clinical programs. Prior to joining Esperion, Dr. Rosenberg served as the executive director and head of cardiovascular and metabolism clinical development for the Forest Research Institute, where he led the advancement of multiple late-stage clinical trials. Earlier in his career, he held leadership roles in clinical development, medical affairs and administration at Sanofi Aventis and Pfizer. Dr. Rosenberg completed his internal medicine residency at The Icahn School of Medicine at Mount Sinai Hospital and holds a medical degree from the Drexel University College of Medicine and a B.A. from Johns Hopkins University.

What is Noah L. Rosenberg's net worth?

The estimated net worth of Noah L. Rosenberg is at least $224,014.05 as of September 22nd, 2020. Dr. Rosenberg owns 29,055 shares of Travere Therapeutics stock worth more than $224,014 as of March 28th. This net worth estimate does not reflect any other investments that Dr. Rosenberg may own. Learn More about Noah L. Rosenberg's net worth.

How do I contact Noah L. Rosenberg?

The corporate mailing address for Dr. Rosenberg and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at [email protected]. Learn More on Noah L. Rosenberg's contact information.

Has Noah L. Rosenberg been buying or selling shares of Travere Therapeutics?

Noah L. Rosenberg has not been actively trading shares of Travere Therapeutics during the last quarter. Learn More on Noah L. Rosenberg's trading history.

Who are Travere Therapeutics' active insiders?

Travere Therapeutics' insider roster includes Steve Aselage (Director), Sandra Calvin (CAO), Laura Clague (CFO), Eric Dube (CEO), Peter Heerma (Insider), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.

Are insiders buying or selling shares of Travere Therapeutics?

During the last year, insiders at the sold shares 19 times. They sold a total of 61,626 shares worth more than $592,956.98. The most recent insider tranaction occured on February, 1st when CEO Eric M Dube sold 19,122 shares worth more than $166,361.40. Insiders at Travere Therapeutics own 3.8% of the company. Learn More about insider trades at Travere Therapeutics.

Information on this page was last updated on 2/1/2024.

Noah L. Rosenberg Insider Trading History at Travere Therapeutics

See Full Table

Noah L. Rosenberg Buying and Selling Activity at Travere Therapeutics

This chart shows Noah L. Rosenberg's buying and selling at Travere Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Travere Therapeutics Company Overview

Travere Therapeutics logo
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $7.71
Low: $7.41
High: $7.97

50 Day Range

MA: $8.26
Low: $7.18
High: $9.32

2 Week Range

Now: $7.71
Low: $5.25
High: $23.17

Volume

776,017 shs

Average Volume

1,235,802 shs

Market Capitalization

$586.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58